Target intelligence / Profile preview

Synaptotagmin-1 (SYT1)

Target
SYT1
Molecular classification
Membrane-trafficking protein, Synaptic vesicle protein, Calcium sensor, Exocytosis regulator, Other (not a classic receptor, transporter, or enzyme)
01

Overview

Synaptotagmin-1 is a synaptic vesicle integral membrane protein serving as the principal calcium sensor for fast, synchronous neurotransmitter release in the central nervous system[1][3][6][8]. It contains an N-terminal transmembrane domain and two cytoplasmic C2 domains (C2A and C2B) that bind Ca\(^{2+}\) and acidic phospholipids[3][5]. Upon Ca\(^{2+}\) influx during an action potential, synaptotagmin-1 interacts with the SNARE complex and phospholipids, triggering rapid synaptic vesicle fusion and neurotransmitter release[1][5][6]. It also acts as a molecular clamp, suppressing spontaneous and asynchronous release through oligomerization and interactions with complexin and SNARE proteins[2][5]. Mutations in SYT1 can impair synaptic function and are associated with some neuropsychiatric disorders[8]. While it is not currently the direct target of any approved therapeutic, it represents a mechanistic node essential for synaptic communication.

Other names
Synaptotagmin ISYT ISyt1p65
02

Mechanism of action

Calcium-dependent activation of fast synaptic vesicle fusion by binding Ca\(^{2+}\) and acidic phospholipids, displacing complexin from the SNARE complex, and enabling SNARE-mediated membrane fusion[1][3].

03

Biological functions

Calcium-dependent neurotransmitter releaseSynaptic vesicle exocytosisRegulation of synchronous and asynchronous neurotransmitter releaseSynaptic vesicle dockingFusion clamp (suppression of spontaneous release)
04

Disease associations

Neurodevelopmental disordersNeuropsychiatric disordersPotential involvement in neurodegenerative disease
05

Safety considerations

As an ubiquitously essential regulator of synaptic transmission, modulation of synaptotagmin-1 risks broad neurological side effects, such as seizures, altered neurotransmission, or neurodevelopmental defects.
06

Interacting drugs

None directly approved or commonly used drugs target synaptotagmin-1 itself. (Some experimental compounds and toxins may alter its function, but no named drug is canonical[6].)
07

Biomarkers

There are currently no established clinical biomarkers directly based on synaptotagmin-1 levels or function.

Beyond the preview

Go deeper on Synaptotagmin-1 (SYT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptotagmin-1 (SYT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call